Late Cornified Envelope 3C as A Cancer Drug Target Or Biomarker

Target Name: LCE3C

NCBI ID: G353144

LCE3C

Late Cornified Envelope 3C as A Cancer Drug Target Or Biomarker

Late cornified envelope 3C (LCE3C) is a protein that is expressed in the late cornified envelope (LE) of human cancer cells. LE is a specialized cell surface structure that is involved in cell-cell adhesion, migration, and invasion. LCE3C is one of the components of the LE and has been shown to play a role in the development and progression of various types of cancer.

Recent studies have suggested that LCE3C may be a potential drug target or biomarker for cancer treatment. In this article, we will explore the biology of LCE3C and its potential as a drug target, as well as the current state of research in this field.

Biology of LCE3C

LCE3C is a transmembrane protein that is expressed in the LE of human cancer cells. The LE is a specialized cell surface structure that is involved in cell-cell adhesion, migration, and invasion. LCE3C is one of the components of the LE and is involved in the formation of the LE and in the regulation of cell surface properties.

Studies have shown that LCE3C plays a role in the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. For example, LCE3C has been shown to be overexpressed in various types of cancer and has been shown to contribute to the development of cancer stem cells.

Potential Drug Target

LCE3C has been shown to be a potential drug target for cancer treatment. Studies have shown that LCE3C can be targeted with small molecules, antibodies, and other therapeutic agents. One of the main reasons for the potential of LCE3C as a drug target is its high expression and stability in cancer cells, as well as its involvement in cell-cell adhesion and migration.

In addition, LCE3C has been shown to play a role in the regulation of cell surface properties, including cell adhesion, migration, and invasion. This suggests that LCE3C may be a useful target for drugs that are designed to modulate these processes.

Current State of Research

Currently, there are several studies ongoing to investigate the potential of LCE3C as a drug target or biomarker for cancer treatment. These studies are focused on the use of small molecules, antibodies, and other therapeutic agents to target LCE3C and its function in cancer.

One of the main goals of these studies is to identify small molecules that can inhibit the activity of LCE3C and prevent its contribution to cancer cell growth and progression. These small molecules may include drugs that are currently being used to treat cancer or that are being explored as potential new treatments.

Another goal of these studies is to determine the mechanisms of action of LCE3C as a drug target. This is an important step in the development of new treatments because it allows researchers to understand how the drug works and how it can be optimized for use.

Conclusion

In conclusion, LCE3C is a protein that is expressed in the late cornified envelope of human cancer cells. It has been shown to play a role in the development and progression of various types of cancer and has potential as a drug target or biomarker for cancer treatment. Current studies are focused on the use of small molecules, antibodies, and other therapeutic agents to target LCE3C and its function in cancer. Further research is needed to understand the mechanisms of action of LCE3C as a drug target and to identify small molecules that can inhibit its activity.

Protein Name: Late Cornified Envelope 3C

Functions: A structural component of the cornified envelope of the stratum corneum involved in innate cutaneous host defense (Probable). Possesses defensin-like antimicrobial activity against a broad spectrum of Gram-positive and Gram-negative bacteria, both aerobic and anaerobic species. Upon inflammation, may regulate skin barrier repair by shaping cutaneous microbiota composition and immune response to bacterial antigens (PubMed:28634035)

The "LCE3C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCE3C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets